Search Results

There are 4644 results for: content related to: Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

  1. You have free access to this content
    Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban

    British Journal of Clinical Pharmacology

    Volume 78, Issue 4, October 2014, Pages: 877–885, Charles Frost, Andrew Shenker, Mohit D. Gandhi, Janice Pursley, Yu Chen Barrett, Jessie Wang, Donglu Zhang, Wonkyung Byon, Rebecca A. Boyd and Frank LaCreta

    Version of Record online : 19 SEP 2014, DOI: 10.1111/bcp.12393

  2. You have free access to this content
    Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

    British Journal of Clinical Pharmacology

    Volume 79, Issue 5, May 2015, Pages: 838–846, Charles E. Frost, Wonkyung Byon, Yan Song, Jessie Wang, Alan E. Schuster, Rebecca A. Boyd, Donglu Zhang, Zhigang Yu, Clapton Dias, Andrew Shenker and Frank LaCreta

    Version of Record online : 22 APR 2015, DOI: 10.1111/bcp.12541

  3. You have full text access to this OnlineOpen article
    Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 76, Issue 5, November 2013, Pages: 776–786, Charles Frost, Sunil Nepal, Jessie Wang, Alan Schuster, Wonkyung Byon, Rebecca A. Boyd, Zhigang Yu, Andrew Shenker, Yu Chen Barrett, Rogelio Mosqueda-Garcia and Frank LaCreta

    Version of Record online : 21 OCT 2013, DOI: 10.1111/bcp.12106

  4. You have full text access to this OnlineOpen article
    Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

    British Journal of Clinical Pharmacology

    Volume 75, Issue 2, February 2013, Pages: 476–487, Charles Frost, Jessie Wang, Sunil Nepal, Alan Schuster, Yu Chen Barrett, Rogelio Mosqueda-Garcia, Richard A. Reeves and Frank LaCreta

    Version of Record online : 10 JAN 2013, DOI: 10.1111/j.1365-2125.2012.04369.x

  5. Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval

    The Journal of Clinical Pharmacology

    Volume 55, Issue 5, May 2015, Pages: 549–555, Charles Frost, Sunil Nepal, Wonkyung Byon, Kenneth Moore, Richard A. Reeves, Rebecca Boyd and Frank LaCreta

    Version of Record online : 14 JAN 2015, DOI: 10.1002/jcph.447

  6. You have full text access to this OnlineOpen article
    Abstracts

    Research and Practice in Thrombosis and Haemostasis

    Volume 1, Issue S1, July 2017, Pages: 1–1451,

    Version of Record online : 23 JUN 2017, DOI: 10.1002/rth2.12012

  7. You have free access to this content
    Abstracts

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue S2, June 2015, Pages: 1–997,

    Version of Record online : 3 JUN 2015, DOI: 10.1111/jth.12993

  8. You have free access to this content
    Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

    Journal of Thrombosis and Haemostasis

    Volume 6, Issue 5, May 2008, Pages: 820–829, P. C. WONG, E. J. CRAIN, B. XIN, R. R. WEXLER, P. Y. S. LAM, D. J. PINTO, J. M. LUETTGEN and R. M. KNABB

    Version of Record online : 26 FEB 2008, DOI: 10.1111/j.1538-7836.2008.02939.x

  9. You have free access to this content
    Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

    The Journal of Clinical Pharmacology

    Volume 56, Issue 5, May 2016, Pages: 628–636, Xiaoli Wang, Giridhar Tirucherai, Thomas C. Marbury, Jessie Wang, Ming Chang, Donglu Zhang, Yan Song, Janice Pursley, Rebecca A. Boyd and Charles Frost

    Version of Record online : 22 DEC 2015, DOI: 10.1002/jcph.628

  10. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study

    Journal of Thrombosis and Haemostasis

    Volume 15, Issue 11, November 2017, Pages: 2125–2137, Y. Song, Z. Wang, I. Perlstein, J. Wang, F. LaCreta, R. J. A. Frost and C. Frost

    Version of Record online : 9 OCT 2017, DOI: 10.1111/jth.13815

  11. You have full text access to this OnlineOpen article
    Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation

    Annals of the New York Academy of Sciences

    Volume 1329, Issue 1, November 2014, Pages: 93–106, Michael S. Hanna, Puneet Mohan, Robert Knabb, Elora Gupta, Charles Frost and John H. Lawrence

    Version of Record online : 5 NOV 2014, DOI: 10.1111/nyas.12567

  12. You have free access to this content
    Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation

    Clinical Cardiology

    Volume 37, Issue 1, January 2014, Pages: 32–47, Irene Savelieva and A. John Camm

    Version of Record online : 19 NOV 2013, DOI: 10.1002/clc.22204

  13. Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose

    Clinical Pharmacology & Therapeutics

    Volume 88, Issue 3, September 2010, Pages: 375–382, T A Leil, Y Feng, L Zhang, A Paccaly, P Mohan and M Pfister

    Version of Record online : 4 AUG 2010, DOI: 10.1038/clpt.2010.106

  14. You have free access to this content
    Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison

    British Journal of Clinical Pharmacology

    Volume 78, Issue 4, October 2014, Pages: 707–717, Yoon K. Loke, Shiva Pradhan, Jessica Ka-yan Yeong and Chun Shing Kwok

    Version of Record online : 19 SEP 2014, DOI: 10.1111/bcp.12376

  15. You have full text access to this OnlineOpen article
    Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study

    Journal of Thrombosis and Haemostasis

    Volume 15, Issue 10, October 2017, Pages: 2017–2028, R. Kreutz, P. B. Persson, D. Kubitza, K. Thelen, S. Heitmeier, S. Schwers, M. Becka and M. Hemmrich

    Version of Record online : 14 SEP 2017, DOI: 10.1111/jth.13801

  16. You have free access to this content
    A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer

    Journal of Thrombosis and Haemostasis

    Volume 10, Issue 5, May 2012, Pages: 807–814, M. N. LEVINE, C. GU, H. A. LIEBMAN, C. P. ESCALANTE, S. SOLYMOSS, D. DEITCHMAN, L. RAMIREZ and J. JULIAN

    Version of Record online : 2 MAY 2012, DOI: 10.1111/j.1538-7836.2012.04693.x

  17. Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 36, Issue 11, November 2016, Pages: e166–e171, Wesley D. Kufel, Adam S. Zayac, David F. Lehmann and Christopher D. Miller

    Version of Record online : 14 OCT 2016, DOI: 10.1002/phar.1836

  18. You have free access to this content
    Multimodal assessment of non-specific hemostatic agents for apixaban reversal

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 3, March 2015, Pages: 426–436, A.-C. Martin, I. Gouin-Thibault, V. Siguret, A. Mordohay, C.-M. Samama, P. Gaussem, B. Le Bonniec and A. Godier

    Version of Record online : 5 FEB 2015, DOI: 10.1111/jth.12830

  19. You have free access to this content
    In vivo increase in thrombin generation by four-factor prothrombin complex concentrate in apixaban-treated healthy volunteers

    Journal of Thrombosis and Haemostasis

    Volume 13, Issue 10, October 2015, Pages: 1799–1805, Y. W. Cheung, S. Barco, B. A. Hutten, J. C. M. Meijers, S. Middeldorp and M. Coppens

    Version of Record online : 21 SEP 2015, DOI: 10.1111/jth.13115

  20. You have free access to this content
    Arterial antithrombotic and bleeding time effects of apixaban, a direct factor Xa inhibitor, in combination with antiplatelet therapy in rabbits

    Journal of Thrombosis and Haemostasis

    Volume 6, Issue 10, October 2008, Pages: 1736–1741, P. C. WONG, C. A. WATSON and E. J. CRAIN

    Version of Record online : 19 JUL 2008, DOI: 10.1111/j.1538-7836.2008.03092.x